Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation (TSX: BU), highlighting the company's transition from development-stage to commercial scale production. The Galesburg facility, which began operations in late 2025, generated third-quarter fiscal year 2026 revenue of $739,000, representing approximately 107% quarter-over-quarter growth. This growth was driven by protein sales and production activity at the site, marking a significant milestone for the company.
Burcon entered calendar year 2025 without a production facility and exited the year meeting its revenue target, underscoring the speed of commercialization following Galesburg's launch. Management indicated that staffing and infrastructure are now in place, positioning the company for incremental volume growth with limited additional fixed costs. This setup supports operating leverage as throughput increases, allowing profitability to improve with scale.
A key aspect of Burcon's growth strategy is the recurring nature of its revenue. Once a customer's product is commercialized, ingredient purchases typically recur on a month-to-month basis. Approximately 65–70% of expected growth is tied to customers already purchasing from Burcon, providing a stable foundation. Additionally, the company has over 200 active projects in its pipeline, which should fuel further expansion. The Galesburg facility serves as the backbone of durable, recurring revenue growth.
Revenue for the quarter increased 1,100% year-over-year, reflecting the impact of the new facility. Looking ahead, Burcon expects double-digit revenue growth in calendar year 2026, driven by increasing production volumes and customer demand. The company's ability to scale quickly while maintaining cost discipline positions it well for continued success.
For more details, the full announcement is available here.
